Also in CRC, assessment is ongoing in the second line settings and beyond. PoC judgment is anticipated for the second half of FY 2025. As for additional data presentation, we are aiming for the ...

Jabbour has also been involved in researching genomic instabilities in patients with low-risk MDS who may need earlier therapeutic ... Jabbour was instrumental in leading the efforts to test triple ...

As the U.S. retreats from global AML standards, compliance and risk professionals must consider the real possibility—and ...

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukemia ...

The following is a summary of “A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older ...

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukemia (AML) by helping ... if a patient is at risk of relapse and offers ...

As such, in conducting their annual risk assessment, VASPs should understand ... Key Indicators of AML Enforcement Focus The recent actions and press releases from the Financial Crimes Enforcement ...

Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeutics announced today an oral presentation at ... acute myeloid leukemia (AML). EVICTION is a first-in-human ...